Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Chronic Lower Back Pain (CLBP)
Interventions: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lymph Node Biopsy, Magnetic Resonance Imaging, Sonrotoclax, Zanubrutinib; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Duarte, California • Irvine, California • Newnan, Georgia

Conditions: Spinal Disease, Anesthesia, Post Operative Pain
Interventions: Lidocaine in Saline, Normal saline; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Spinal Cord Injuries (Complete and Incomplete)
Interventions: Transauricular vagus nerve stimulation; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Hypertension
Interventions: Low-level tragus stimulation, Sham stimulation; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 24
States / cities: Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more

Conditions: High-grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells; Biological
Lead sponsor: University of Florida; Other
Eligibility: 4 Years to 30 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2045
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post-viral Anosmia, Anosmia, Hyposmia
Interventions: Sniff Training Kits; Other
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 60 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Baltimore, Maryland • Charleston, South Carolina • Charlottesville, Virginia

Conditions: Type 2 Diabetes
Interventions: Zenagamtide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 55
States / cities: Phoenix, Arizona • La Jolla, California • La Mesa, California + 48 more

Conditions: Breast Cancer Recurrent
Interventions: Reirradiation; Radiation
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Chronic Venous Disease, Chronic Venous Insufficiency, CVI, Venous Thrombosis, Thrombosis (Stent Thrombosis), Thrombosis, Venous, Embolism and Thrombosis, Thrombectomy
Interventions: Recanalization and debulking; Device
Lead sponsor: Intervene, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Interventions: Debamestrocel - MSC-NTF (NurOwn), Placebo; Biological
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 15
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Multiple Myeloma (MM)
Interventions: PET-enabled dual-energy CT imaging, X-ray dual-energy CT imaging; Diagnostic Test
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Fall
Interventions: Real-life Dual-Task Training, Fall Prevention Education; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 65 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Acute Back Pain
Interventions: Battlefield auricular acupressure, Sham; Procedure
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Multiple Sclerosis
Interventions: 1000mg acetaminophen or placebo; Drug
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: KAN-001, Pembrolizumab; Biological
Lead sponsor: Kanvas Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Maumee, Ohio

Conditions: Tonsillectomy, Pharyngoplasty, Suzetrigine, Opioid, Postoperative Pain, Acute Pain
Interventions: Suzetrigine, Acetaminophen, oxycodone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Triple Negative Breast Cancer
Interventions: TheraBionic P1; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 22 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Airway Disorder
Interventions: High flow, Low Flow; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Hypertension, Hypertension
Interventions: Emergency Department-Initiated Team-Based Care, Usual Care; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Brownstown, Michigan • Dearborn, Michigan • Detroit, Michigan + 1 more

Conditions: Pelvis Fractures, Acetabulum Fractures
Interventions: Immediate Weight Bearing Pelvis, Delayed Weight Bearing Pelvis, Immediate Weight Bearing Acetabulum, Delayed Weight Bearing Acetabulum; Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Colton, California • Indianapolis, Indiana + 3 more

Conditions: Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions: Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Mechanistic Evaluation of Polypharmacy Effects for Pain

Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds

Pilot Testing of Vagus Nerve Stimulation for Early Spinal Cord Injury Recovery

Neuromodulation in Patients With Pulmonary Arterial Hypertension

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)

Navigating the Clinical Research Process for Mild Cognitive Impairment

SniffTrain: Effectiveness of Sniff Training in the Treatment of Post-Viral Anosmia

AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

aPBI Re-irradiation

The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

PET-Enabled Dual-Energy CT in Multiple Myeloma

Real-life Dual-Task Training for Older Adults at Risk to Fall: A Pilot Clinical Trial

Battlefield Acupressure for Acute Back Pain Management in the Emergency Department

Effect of Acetominophen an Gait Fatigue in Multiple Sclerosis

A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer

Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

Optimizing High Flow Nasal Cannula Oxygenation in Pediatric Airway Procedures

Emergency Department-Initiated Team-Based Care for Severe Hypertension

Weight Bearing After Pelvis and Acetabulum Fracture Fixation

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV